使

Hironori Suzuki1,2, Kosuke Yoshida1,2, Akira Yokoi3,4

  • 1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

NPJ precision oncology
|November 11, 2025
PubMed
概括

聚 ((ADP-ribose) 聚合酶抑制剂 (PARPi) 在卵巢癌中表现有前途,但发生耐药性. 空间转录学揭示了midkine (MDK) 信号驱动阻力,高SDC4表达与高度血清性卵巢癌 (HGSOC) 患者的低生存率有关.